9 Evidence-Based Facts About Testosterone Therapy for Women in Menopause Before You Decide Whether to Try It
The number of women who've told me they felt 'broken' because nothing — not estrogen, not therapy, not sleep hygiene — was touching their complete loss of desire or that flat, foggy feeling is staggering. For many of them, testosterone turned out to be the missing piece. The frustration isn't just that it's hard to get; it's that most of them had never once been told it was an option for women at all.
Learn more about Rose →Women produce testosterone naturally — and levels decline well before the final menstrual period
Testosterone is produced in the ovaries and adrenal glands throughout a woman's life, peaking in her mid-twenties and falling gradually from there. By the time a woman reaches her late forties or early fifties, circulating testosterone levels may already be half of what they were at peak. This slow decline means symptoms can creep in years before the menopause transition is even on the radar, making the hormonal connection easy to miss.
The strongest evidence for testosterone therapy in women is for hypoactive sexual desire disorder (HSDD)
Multiple randomised controlled trials and a landmark 2019 global consensus statement from the International Society for the Study of Women's Sexual Health concluded that testosterone therapy is effective for postmenopausal women with HSDD — a persistent, distressing loss of sexual desire. The benefit is clinically meaningful: women in trials reported not just increased desire but improved arousal, orgasm frequency, and overall sexual satisfaction. This is not a subtle effect; it is one of the more robust findings in the menopause pharmacology literature.
There are no testosterone products formally approved for women in most countries — which creates a real prescribing gap
In the United States, the United Kingdom, and most of Europe, no testosterone product is currently licensed specifically for women, meaning any prescription is technically off-label. Clinicians who are aware of the evidence do prescribe it, but many are hesitant to do so without a regulatory green light, leaving a large treatment gap. This regulatory lag is not a reflection of the evidence quality — it largely reflects the historical underfunding of women's health research and a commercial calculation that a low-dose female-specific product would not be profitable enough to pursue approval.
Dosing for women is significantly lower than for men — and getting it wrong matters
Therapeutic testosterone levels for women target the upper end of the normal female physiological range, which is roughly 10 to 70 ng/dL — far below male reference ranges. Because available products are almost universally formulated for men, clinicians must prescribe a fraction of the standard male dose, often from a compounded preparation or by directing patients to use a small amount of a male gel. This dosing complexity increases the risk of inadvertent supraphysiological exposure if patients are not carefully monitored.
Virilisation side effects are real but uncommon at physiological doses — and largely reversible
At doses that keep blood levels within the normal female range, unwanted androgenic effects such as acne, facial hair growth, voice changes, and clitoral enlargement are uncommon in clinical trials. When they do occur, they are typically mild and resolve after dose reduction or discontinuation — the exception being voice changes, which may be slow to reverse. Regular blood monitoring every three to six months during the initiation phase helps catch rising levels before side effects become established.
The evidence on testosterone for mood, energy, and cognition is promising but not yet definitive
Several observational studies and smaller trials suggest that testosterone supplementation may improve fatigue, low mood, and aspects of cognitive function such as verbal memory and processing speed in menopausal women. However, these outcomes have not been as rigorously studied as sexual function, and the effect sizes are more variable. The physiological rationale is solid — androgen receptors are distributed throughout the brain, including in regions involved in mood regulation and memory — but larger dedicated trials are still needed before strong conclusions can be drawn.
Current evidence does not show increased breast cancer risk at physiological doses — but long-term data are limited
A 2023 meta-analysis examining testosterone therapy and breast cancer risk found no statistically significant increase in risk at doses targeting normal female physiological levels, and some researchers have hypothesised a potentially protective role through conversion dynamics. However, the longest studies to date extend only about five years, and robust long-term safety data equivalent to what exists for estrogen simply do not yet exist. Women with a personal or strong family history of hormone-sensitive breast cancer should discuss this specifically with a specialist rather than extrapolating from general population data.
Testosterone therapy is not a replacement for estrogen — it typically works best alongside it
Clinical guidelines from the British Menopause Society and the Endocrine Society generally recommend that testosterone therapy in menopausal women be used alongside estrogen, not as a standalone treatment. Estrogen addresses the broader symptom landscape — vasomotor symptoms, vaginal atrophy, bone density — while testosterone more specifically targets desire and, potentially, energy and cognition. Using testosterone alone without addressing estrogen deficiency may leave the majority of a woman's symptom burden untreated.
Blood testing to confirm low testosterone before starting — and to monitor during treatment — is considered best practice
Because testosterone symptoms overlap significantly with those of estrogen deficiency, thyroid dysfunction, depression, and iron deficiency anaemia, testing before treatment helps confirm that low androgens are actually contributing to symptoms and establishes a meaningful baseline. The most reliable measurement is total testosterone using a sensitive assay, ideally taken in the morning when levels peak; free testosterone calculations are less standardised and should be interpreted cautiously. Ongoing monitoring prevents inadvertent overdosing and provides a documented rationale for continued prescribing in clinical settings where off-label prescribing requires clear justification.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.